Neurosoft Bioelectronics Wins China’s Provincial Competition as “Fujian’s Iconic BCI Product”
Geneva, Switzerland and Xiamen, Fujian — October 16th, 2026 — Neurosoft Bioelectronics, a developer of high-bandwidth brain-computer interfaces (BCIs), today announced that it has won a gold prize in the 2026 Fujian Global Innovation and Entrepreneurship Competition in the Biotechnology track.
Figure 1 - Ludovic Serex, Phd., Co-founder and CTO of Neurosoft a explaining fabrication requirements to local ecosystem's suppliers and OEMs in Xiamen at a symposium organized by the by the Municipal S&T Bureau.
A strategic moment for BCI in China
Neurosoft’s selection comes as China rapidly expands its investment and industrial policy support for brain-computer interfaces. BCI has been designated a future industry under China’s 15th Five-Year Plan (2026–2030), with national policy calling for development across fundamental research, technology demonstration, commercial applications and supporting business and regulatory systems.
According to the Linggang Group and Blue Ocean Capital Group, two independent firms leading BCI investments in China, the country has invested close to US$1 billion in BCI in H1 of 2026 to date, overtaking the United States in bi-annual BCI spending for the first time.
Marking a historic transition of BCI technology from the laboratory into clinical practice, on March 13, 2026, China approved the world’s first invasive BCI medical device for chronic commercial use. Neurosoft is building for this next phase of the industry. With hardware optimised for safety and indication-specific signal quality, Neurosoft’s SOFT ECOG product is entering its industrialisation phase.
As Neurosoft expands its clinical footprint internationally, the company aims to acquire a large scale dataset of labelled human cortical control of movement, simultaneously spanning cortical regions implicated in motor attention, planning, decision-making, execution, and sensory integration; A most comprehensive view of a dynamical system evolved to optimise dexterous high-dimensional mechanical control under feedback.
This unique dataset may become a key differentiator in global leadership in another, more mature, future industry of the 15th Five-Year Plan: Humanoid Robots.
Neurosoft is confident in finding key position in Fujian’s BCI launchpad
Neurosoft’s proposal has been selected from over a thousand projects accepted to the preliminaries. The competition was organised by the Talent Work Leading Group Office of the CPC Fujian Provincial Committee with support from governmental departments of several cities and districts.
Fujian, with 2025 GDP of circa USD 850 billion and annual R&D spending of USD 18 billion, represents an unusually strong platform for international high-tech growth. For example, the city of Xiamen contains one of China’s first special economic zones, established in 1980. The Pilot Free Trade Zone holds the rare power to enact its own laws within the zone, adopting rules for emerging technologies without waiting on national legislation. They introduced 391 policy measures, 74 of them national firsts, including China’s first bonded-maintenance pilot for third-party medical devices. In 2025, Xiamen’s foreign trade reached a record USD 132 billion.
Figure 2 - Ludovic Serex and Sam Hosovsky, Neurosoft’s CTO and VP of NeuroAI respectively, discussing implementation needs in Xiamen Bio Bay, a medical device R&D hub producing over 80% of Fujian’s new IP in the category, contained inside the Pilot Free Trade Zone.
Neurosoft is pursuing a staged global strategy to develop next generation of BCI products which are safe to reach the mass market. A feat not achievable without a mature industrialisation ecosystem and policy alignment.
The provincial recognition poises Neurosoft as Fujian’s flagship high-bandwidth BCI company, developing next-generation neural interfaces capable of recording and decoding large-scale brain activity for treatment of epilepsy and high degree-of-freedom control of one’s own paralysed body.
Xiamen partnership creates a pathway from research to clinical deployment
Neurosoft aims to collaborate closely with the Neurotechnology Innovation and Impact Institute (N3I) of West China Hospital of Sichuan University, which has established itself as a platform for translating neurotechnology from scientific research toward clinical and commercial impact. N3I operates in both Xiamen and Chengdu, with Gerwin Schalk, Ph.D., serving as Director in Xiamen.
“We are excited to work with Neurosoft to translate advanced high-bandwidth BCI technology into clinical applications. Our collaboration will establish the infrastructure to evaluate Neurosoft’s devices, to innovate new neurosurgical protocols based on them, and to create a pathway toward deploying these devices across Fujian Province.”
Gerwin Schalk, Ph.D., Co-Director, Neurotechnology Innovation and Impact Institute
Figure 3 - Neurosoft's VP of NeuroAI, Sam Hosovsky, at the competition's award ceremony in Xiamen with Prof. Schalk on right with members of the competition staff and Municipal S&T Bureau.
For Neurosoft, N3I provides a critical one-stop translational platform connecting neurotechnology research, clinical validation, entrepreneurship and commercialisation.
The broader West China Hospital ecosystem also gives Neurosoft access to one of China’s largest academic medical networks, creating an important gateway for future patient recruitment and clinical research. West China Hospital of Sichuan University has an extensive clinical and regional healthcare network and is ranked #1 in research and amongst the top 5 neurology and neurosurgery centres in China.
About Neurosoft Bioelectronics
Neurosoft Bioelectronics develops high-bandwidth brain-computer interfaces and AI systems for decoding human brain activity. The company’s mission is to build scalable neural interfaces capable of reverse engineering distributed neural circuits, one mental process at a time.
Media Contact
Neurosoft Bioelectronics
Alexandra Konstantinova
alexandra.konstantinova@neurosoft-bio.com
Neurosoft Bioelectronics Partners with Mila to Advance AI-Powered Brain-Computer Interfaces
Neurosoft Bioelectronics Partners with Mila to Advance AI-Powered Brain-Computer Interfaces
The partnership brings together Mila's world-leading AI research institute with Neurosoft's minimally invasive Brain Computer Interface platform, with the goal of accelerating the development of a cortical foundation model. Together, the two organizations aim to unlock new frontiers in neural data and patient care.
GENEVA & MONTRÉAL — September 24, 2026 — Neurosoft Bioelectronics and Mila are pleased to announce a new partnership to accelerate the development of AI-powered neural interfaces for patients with severe neurological conditions. Neurosoft is a neurotechnology company developing safe and scalable brain-computer interfaces, while Mila is one of the world's leading AI research institutes. Through the partnership, Neurosoft joins Mila's industry network, gaining access to its AI research community to advance this work.
Neurosoft's proprietary BCI platform leverages stretchable and minimally invasive technology to advance scalable brain interfaces that reduce risks, while integrating artificial intelligence to extract actionable insights from brain recordings. Alongside its BCI hardware, the company is building a cortical foundation model trained on large-scale neural recordings, analogous to how large language models are trained on vast text corpora, with the goal of better understanding how neural recordings translate into various brain functions.
Compared to text corpora, however, brain data remains many orders of magnitude scarcer. Overcoming this bottleneck is the defining technical challenge in building foundation models for the brain: it demands sample-efficient algorithms that learn more from less data, and models that build knowledge of the brain directly into how they learn. Mila is home to one of the highest concentrations of world-class researchers working on exactly these problems, whether through approaches inspired by the brain or discovered in applied mathematics.
Through this partnership, Neurosoft Bioelectronics will expand its access to Mila's AI research community and its network of close to 2,000 researchers and professionals, supporting the advancement of its NeuroAI program. The collaboration aligns with Mila's core focus on AI and Health and its mission to build AI that serves society.
"Building AI that understands the brain is one of the most demanding tests we can set for sample-efficient learning, and it's exactly the kind of challenge our research community was built to tackle. Neurosoft's partnership gives our NeuroAI researchers a direct path from foundational algorithms to real-world clinical impact. It's a strong example of what our work around AI and Health is designed to do: connect deep research with solutions that can ultimately make a difference for patients."
— Stéphane Létourneau, Executive Vice President, Mila
"A cortical foundation model has the potential to do for BCIs what large language models did for natural language processing: unlock capabilities that scale across patients, conditions, and clinical contexts in ways that current algorithms simply cannot. Partnering with Mila gives us the AI research depth to actively pursue this vision. For Neurosoft, this marks an important step toward building a platform that doesn't just record the brain, but can understand it, and translate that understanding into better outcomes for patients."
— Nicolas Vachicouras, PhD, CEO & Co-Founder, Neurosoft Bioelectronics
"This partnership formalizes something we've already seen work in practice. Our ongoing collaboration with Prof. Guillaume Lajoie's lab at Mila has been one of the most productive scientific partnerships Neurosoft has engaged in. By combining our neural recording platform with Mila's AI expertise, we are working towards better understanding various brain processes. Joining Mila's network now gives us the resources and community to extend that momentum towards a broad range of cortical applications."
— Nicolas Gninenko, PhD, Neuroscientist, Neurosoft Bioelectronics
ABOUT MILA
Founded by Professor Yoshua Bengio, Mila is one of the world's leading AI research institutes, bringing together close to 2,000 researchers & professionals shaping the future of intelligence. A non-profit organization based in Montreal, Mila is recognized for its scientific contributions, global innovation partnerships, leadership in safe & responsible AI, and acceleration of AI venture creation. It was created through a unique partnership between Université de Montréal and McGill University to advance scientific breakthroughs for the benefit of all. Mila is supported by the Government of Canada, the Government of Quebec, and more than 150 industrial partners. For more information, visit mila.quebec.
ABOUT NEUROSOFT BIOELECTRONICS
Neurosoft Bioelectronics is decoding the brain at scale. The company builds soft, stretchable neural interfaces that conform to the surface of the cortex: capturing activity across entire brain networks without penetrating tissue, through a minimally invasive procedure rather than open surgery. By making large-scale cortical recording safe and routine, Neurosoft generates the high-quality brain data needed to train foundation models that translate neural activity into movement, speech, perception, and beyond. Spun out of EPFL and based in Geneva and New York, the company has advanced its technology from the lab into first-in-human clinical studies in the US and Europe. Learn more at neurosoft-bio.com.
Media Contact
Nicolas Vachicouras, PhD – Co-Founder & CEO
+41 76 429 12 02 (CH) | +1 914 233 4172 (US)
169 Madison Ave # 11497, New York, NY 10016
Chemin des Mines 15 bis, 1202 Geneva, Switzerland
Neurosoft Bioelectronics Names Sam Hosovsky Vice President of NeuroAI
Appointment marks Neurosoft's expansion beyond stretchable BCI hardware into neural data and AI models for decoding the human cortex, advancing its goal of turning brain interfaces into products people genuinely need.
Appointment marks Neurosoft's expansion beyond stretchable BCI hardware into neural data and AI models for decoding the human cortex, advancing its goal of turning brain interfaces into products people genuinely need.
GENEVA & NEW YORK — July 7, 2026 — Neurosoft Bioelectronics, a neurotechnology company developing scalable and safe brain-computer interfaces (BCIs), today announced the appointment of Sam Hosovsky as Vice President of NeuroAI. Hosovsky will lead the company's NeuroAI strategy and the neural foundation models set to power the next generation of high-performance brain interfaces, extending Neurosoft's mission from the stretchable electrodes it places on the cortex to the intelligence that makes the resulting data useful.
The appointment marks the next stage of Neurosoft's evolution, broadening from stretchable BCI hardware into the neural data and AI systems that turn recordings into real-world products, targeting a range of neural activity across the conditions its platform addresses, including motor restoration for people with paralysis. That work positions Neurosoft as a bridge between computational neuroscience and machine learning, running in both directions: bringing frontier AI to the problem of brain decoding, and the open problems of brain decoding back to frontier AI: an AI4Brain and Brain4AI exchange that few organizations are positioned to enable.
"Our soft electrode platform gives us neural data at a quality and scale no other approach can safely match, but data and hardware are only half the story," said Nicolas Vachicouras, PhD, CEO and Co-Founder of Neurosoft Bioelectronics. "Turning that data into products people genuinely need, such as restoring movement for people with paralysis, demands as much ambition in AI as in engineering. Sam has spent his whole career at that intersection, always starting from the end user. Bringing him on to lead NeuroAI is the natural next chapter for Neurosoft."
Hosovsky joins Neurosoft after nearly 5 years building software for intracranial BCI users through the uCat App, working alongside leading motor-BCI startups, research laboratories, clinicians, and patient organizations. His work has centered on translating intracranial signals into practical products for people with paralysis, giving him a rare perspective that spans the end-user experience, AI, and neural decoding, a perspective he set out in the first book dedicated to intracranial motor-BCI applications, "Your Cortical Avatar Technology."
"For nearly a decade I've been searching for a BCI that could reliably decode dexterous, whole-body movement and truly improve the lives of people with paralysis, at a scale that could eventually reach millions," said Hosovsky. "The field has spent years perfecting hardware; the opportunity now is to start with the user and work backwards to the technology. Neurosoft is the only interface that can chronically span all of the cortical areas involved in movement at once. Our challenge is to interpret that newfound orchestra as a coherent symphony."
Before joining Neurosoft, Hosovsky built a career architecting software platforms at the intersection of artificial intelligence, life sciences, and emerging technologies, spanning laboratory automation, clinical-trial infrastructure, generative AI, and extended reality, leading multidisciplinary engineering organizations and delivering production systems adopted by global pharmaceutical and research organizations. He is also a Partner at Jumpspace Ventures, one of the world's most active brain-
technology investment firms, where he leads technical due diligence across high-resolution BCIs, connectome-inspired AI, neural foundation models, and neural tissue engineering.
About Neurosoft Bioelectronics
Neurosoft Bioelectronics is a neurotechnology company developing stretchable and scalable brain-computer interfaces, with headquarters in Geneva, Switzerland and a US subsidiary in New York. Spun out of EPFL, the company's proprietary soft, stretchable electrode platform provides full-cortical access without penetrating brain tissue, enabling high-quality neural data acquisition. Neurosoft holds ISO 13485:2016 certification and has conducted first-in-human clinical studies at UTHealth Houston (US) and UMC Utrecht (Netherlands). Learn more at www.neurosoft-bio.com.
Media Contact
Nicolas Vachicouras, PhD — CEO & Co-Founder nicolas@neurosoft-bio.com
+41 78 876 14 69 (CH) | +1 914 233 4172 (US)
169 Madison Ave # 11497, New York, NY 10016 // Chemin des Mines 15bis, 1202 Geneva, Switzerland
Neurosoft Bioelectronics welcomes two leading advisors in neuro AI
Neurosoft Bioelectronics welcomes two leading advisors in neuro AI
Geneva, Switzerland, July 31 2025 - Neurosoft Bioelectronics SA, a Swiss company with a US presence in New York, developing scalable implantable brain-computer interfaces, is pleased to announce that Prof. Guillaume Lajoie and Prof. Martin Schrimpf have joined as scientific advisors to support the company’s strategy in neuro artificial intelligence and foundation brain modeling.
Geneva, Switzerland, July 31 2025 - Neurosoft Bioelectronics SA, a Swiss company with a US presence in New York, developing scalable implantable brain-computer interfaces, is pleased to announce that Prof. Guillaume Lajoie and Prof. Martin Schrimpf have joined as scientific advisors to support the company’s strategy in neuro artificial intelligence and foundation brain modeling.
This strategic addition reinforces Neurosoft’s ambition to build a foundation model of the brain trained on large-scale brain recordings, enabled by the company’s soft and high-resolution electrodes that can safely and stably cover a large cortical surface.
Prof. Guillaume Lajoie is Associate Professor at the University of Montréal and a core academic member of Mila, the Quebec AI Institute. His research explores mathematical tools and algorithms for brainmachine interfaces, and contributes to the responsible use of AI in scientific and clinical contexts. He was a leading author of POYO, one of the first neuro foundation models designed to decode large-scale neural activity from spike-level data.
Prof. Martin Schrimpf is a tenure-track Assistant Professor at EPFL and leads the NeuroAI research group at the EPFL Neuro-X Institute. His work combines deep learning, neuroscience, and cognitive science to build artificial neural networks that reproduce the brain’s internal representations and align with human behavior. After completing his PhD at MIT, he contributed to landmark studies in vision and language, and is the founder of the Brain-Score.org benchmarking platform.
“As we advance our clinical studies, we are exploring how our scalable and high-quality brain recordings could enable the development of foundation models,” said Dr. Nicolas Vachicouras, CEO and Co-Founder of Neurosoft Bioelectronics. “Guillaume and Martin bring exceptional expertise at the intersection of neuroscience and AI. Their guidance will be key as we work toward better brain decoding, biomarker discovery, and ultimately a general-purpose model of human brain function and cognition.”
Switzerland is emerging as a leader in AI foundation model research. Its national supercomputing center in Lugano inaugurated the Alps supercomputer in 2024, now ranked among the fastest systems in the world. The system has already been used to train open-source large language models developed by EPFL in collaboration with ETH Zurich, the Swiss National Supercomputing Centre (CSCS), and the Swiss Data Science Center (SDSC). As a spin-off from EPFL, Neurosoft Bioelectronics benefits from Switzerland’s strong academic and AI ecosystem. This positions the company to bridge high-quality clinical brain data with advanced AI models, enabling next-generation brain computer interfaces.
Swiss company sets record for most electrodes in a soft and stretchable brain interface tested in a human
Swiss company sets record for most electrodes in a soft and stretchable brain interface tested in a human
Geneva, Switzerland / Utrecht, Netherlands – 27-Feb-2025 – Neurosoft Bioelectronics SA, a Swiss neurotechnology startup based at Campus Biotech in Geneva, has achieved a major milestone with the successful testing of its high channel count brain interface in the first two human patients. This milestone was reached in February 2025 at University Medical Center (UMC) Utrecht, where a team led by Professor Maeike Zijlmans employed the device during epilepsy surgery.
This novel brain interface is designed to detect key epilepsy biomarkers - high-frequency oscillations and fast ripples - allowing surgeons to identify epileptic tissue with unprecedented precision during the procedure. With 64 sensing channels embedded in a stretchable material that is 1,000 to 100,000 times softer than conventional electrodes, the device conforms seamlessly to the brain's surface. This softness improves comformability with the brain, while ensuring high-resolution neural recordings, helping neurosurgeons distinguish between healthy and epileptic tissue more accurately, thereby reducing the risk of either excessive or insufficient tissue removal.
"We are pushing the frontier of neurotechnology focusing on materials that are intended to interface seamlessly with the brain," said Nicolas Vachicouras, CEO and co-founder of Neurosoft Bioelectronics. "This milestone solidifies our leadership in soft, stretchable brain interfaces and paves the way for broader applications in neuroprosthetics and brain-computer interfaces."
"The Neurosoft flexible grid has been developed according to our clinical needs. The flexibility can be especially useful for recording small epileptic activity, like high frequency oscillations and for checking the surgical borders after initial tissue resection." said Prof. Maeike Zijlmans, epilepsy specialist at UMC Utrecht.
These first two successful trials mark the beginning of a larger, 12-patient study at UMC Utrecht, designed to validate the technology for broader clinical use. The ultimate goal is to secure European regulatory approval and make this high-resolution technology available to epilepsy surgery centers across Europe.
The success of this initiative is the result of close collaboration between Neurosoft Bioelectronics and UMC Utrecht, demonstrating how startups and hospitals can work together to bring cutting-edge medical technologies into real-world clinical settings. This work has been made possible through the support of the Wyss Center for Bio and Neuroengineering and Fongit, which have played a key role in fostering Neurosoft Bioelectronics’ technological and clinical advancements. Additionally, the study conducted at UMC Utrecht is funded by the European Research Council (ERC), reflecting the project's significance in advancing neurotechnology and epilepsy research.
About Neurosoft Bioelectronics
Neurosoft Bioelectronics Ltd. is a neurotechnology spin-off from the Swiss Federal Institute of Technology in Lausanne (EPFL) and accelerated by the Wyss Center for bio and neuroengineering. Neurosoft Bioelectronics is developing the next generation of soft minimally invasive brain interfaces for the treatment of severe neurological disorders. Its main product is a fully implantable Brain-Computer Interface (BCI) to treat severe tinnitus, a condition that affects 120M people worldwide. It is also developing a family of brain interfaces intended for monitoring during brain tumor and epilepsy resection surgery.
About UMC Utrecht
UMC Utrecht is one of the top-ranked academic medical centers in Europe with the core tasks of care, research and education. With more than 12,000 employees, UMC Utrecht is one of the largest public healthcare institutions in the Netherlands and the largest employer in the region. Our mission: together we improve the health of people and create the care of tomorrow. Together we create more value, because we believe that every person counts.
Research at UMC Utrecht is concentrated in six multidisciplinary programs, each with a number of disease targets. ‘Brain’ is one of these research programs. UMC Utrecht collaborates with many regional, national and international partners in the field of care, research and education.
Contacts:
Neurosoft Bioelectronics (Media relations) Nicolas Vachicouras nicolas@neurosoft-bio.com CH: +41 78 876 1469 / US: +1 914 233 4172
UMC Utrecht (Spokesperson) Margreeth Fernhout m.w.fernhout-4@umcutrecht.nl NL: +31 652 803 031